Imeglimin improves mitochondrial quality and protects against lipopolysaccharide-induced acute lung injury by enhancing TXNIP promoter methylation.
This study explores the protective effects and mechanistic pathways of imeglimin in models of lipopolysaccharide (LPS)-induced acute lung injury (ALI). Imeglimin administration significantly enhanced survival rates, mitigated pulmonary edema, and attenuated histopathological lung damage in murine subjects. Furthermore,...